In China for Global｜Teddylab participated in the "OCT DAH 2022" 2022 German Clinical Trial Outsourcing Conference
2022-11-30 22:18:56
On November 30th, Teddylab was invited to participate in the "OCT DAH 2022" 2022 German Clinical Trial Outsourcing Conference, introducing to European industry peers that Teddylab is a leading enterprise in China's CRO central laboratory, providing professional biomedical and medical device clinical research laboratory services, including providing central laboratory testing and central pathology services, related project management, logistics management, and data management. At the exhibition, as a leading central laboratory in China among the participating institutions, Teddylab attracted many European pharmaceutical companies interested in the Chinese market to consult on policies and regulations related to clinical trials in China. At the same time, Teddylab also used this opportunity to participate in the OCT DAH International Exhibition to help Chinese companies find excellent overseas laboratory partners in Europe, providing global one-stop central laboratory services for domestic and foreign customers.
▲ 观合展位
▲ 图为观合海外美国和欧洲运营负责人（荷兰）：林展民博士
Teddylab
▲ The picture shows Dr. Lin Zhanmin, the head of overseas operations in the United States and Europe of Teddylab
Up to now, Teddylab has participated in nearly 500 drug clinical trials, cooperated with the sponsor to pass the on-site inspections of the National Medical Products Administration and provincial bureaus for many times, supported more than 20 new drugs to pass the CDE application for listing, and accumulated rich laboratory technology and project management experience in the research and development fields of solid tumors, non-solid tumors, cell immunotherapy, diabetes, hepatitis, cardiovascular diseases, vaccines and other subdivisions.
In recent years, Teddylab has actively laid out a global layout, helping domestic and foreign biomedical enterprises to "go global" from China and "come in" from abroad. Upholding the core concept of "In China, For Global", Teddylab has been constantly seeking laboratory solutions for sponsors to carry out MRCT clinical research in China and overseas simultaneously. At present, Teddylab has established a team of nearly 20 people with senior overseas project management experience, and has carried out international strategic cooperation with dozens of overseas laboratories, including ICON, PAREXEL, Cerba Research, HematoGenix, NeoGenomics, mlm Medical Labs, ViroClinics-DDL, and PPC Jiasheng in Taiwan, to expand the service capabilities of central laboratories to the world, and continuously provide one-stop integrated services such as bioanalysis and central laboratories for innovative drug companies, medical device and vaccine companies. It has helped more than 20 biomedical companies to pass the inspection of the State Food and Drug Administration and overseas regulatory agencies.
▲Teddylab had an exchange with the head of Cerba Research, an important partner
▲ Teddylab engaged in an exchange with the head of the leading European central laboratory, German mlm Medical Labs
Up to now, Teddylab has efficiently and flexibly promoted the implementation of dozens of international multi-center clinical trials, thus helping drugs to be developed simultaneously in China and overseas, and helping Chinese pharmaceutical companies to go global. Guanghe Pharmaceutical will continue to create opportunities for international cooperation, actively promote the implementation of international multi-center clinical trial projects, empower domestic and foreign pharmaceutical companies in new drug research and development, and achieve win-win cooperation.
▲观合医药与重要合作伙伴Cerba Research负责人进行交流
▲观合医药与欧洲中心实验室龙头德国mlm Medical Labs负责人进行交流
About "OCT DACH 2022"
"Outsourcing in Clinical Trials DACH 2022" was held in Munich, Germany on November 30, 2022. The two-day OCT DACH will focus on the operational challenges in clinical development in Germany, Austria and Switzerland. Delegates will discuss common challenges and trends affecting the region, including defining contractual relationships and steps to maximize benefits from external suppliers, incentivizing good relationships with CROs, and establishing clear delivery dates.
